

**Table 1: Available vaccine efficacy data (last updated March 4, 2021)**

Vaccine	Symptomatic disease: all	Symptomatic disease: D614G		Any infection: D614G		Asymptomatic: All	Severe disease: D614G		Symptomatic disease: B.1.1.7	Symptomatic disease: B.1.351	Severe disease: B.1.351	Symptomatic disease: P.1	Severe disease: P.1	Notes	Source(s)
	Complete regimen	1st dose	Complete regimen	1st dose	Complete regimen	Complete regimen	1st dose	Complete regimen	Complete regimen	Complete regimen	Complete regimen	Complete regimen	Complete regimen		
Pfizer-BioNTech		Trial (Day 0-21): 52% (29.5% to 68.4%) Israel SHEBA (Day 15-28): 85% (71% to 92%) Israel CLALIT (Day 14-20): 57% (50% to 63%) Israel Maccabi (Day 13-24): 51.4% (-7.2% to 78.0%) England (Day 28+, 80+ yrs): 57% (48% to 63%)	Trial: 94.6% (90.3% to 97.6%) Israel SHEBA (Day 15-28): 75% (72% to 84%) Israel CLALIT: 94% (87 to 98%) England (80+ yrs): 88% (84% to 90%)	UK SIREN (Day 21+): 72% (58% to 86%) Israel SHEBA (Day 15-28): 75% (72% to 84%) Israel CLALIT (Day 14-20): 46% (40% to 51%)	UK SIREN: 86% (76% to 97%) Israel CLALIT: 92% (88 to 95%)		Trial: 100% (-52% to 100%) Israel CLALIT (Day 14-21): 62% (39% to 80%)	Trial: 75% (-152.6% to 99.5%) Israel CLALIT: 92% (75% to 100%)						Trial, Israel and UK studies assumed to apply to wildtype/D614G/B.1.1.7 outcomes	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2034577">www.nejm.org/doi/full/10.1056/NEJMoa2034577</a> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext">www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext</a> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2101765">www.nejm.org/doi/full/10.1056/NEJMoa2101765</a> <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399">papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399</a> <a href="https://www.medrxiv.org/content/10.1101/2021.01.27.21250612v1">www.medrxiv.org/content/10.1101/2021.01.27.21250612v1</a> <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963532/COVID-19_vaccine_effectiveness_surveillance_report_February_2021_FINAL.pdf">assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963532/COVID-19_vaccine_effectiveness_surveillance_report_February_2021_FINAL.pdf</a>
Moderna			Trial: 94.1% (89.3% to 96.8%)	Trial (Day 0-21): 89.6% (85.2% to 92.6%)			Trial: 100% (NE)							Trial assumed to apply to wildtype/D614G/B.1.1.7 outcomes	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2035389">www.nejm.org/doi/full/10.1056/NEJMoa2035389</a>
Oxford-AstraZeneca	Trial (UK, SA, Brazil): 66.7% (57.4% to 74.0%)	Trial (UK): 74.2% (65% to 81%)		Trial (UK): 51.9% (42.0% to 60.1%)				Trial (variant-specific): 74.6% (41.6% to 88.9%)	Trial (variant-specific): 10.4% (-76.8 to 54.8%)			Trial (Brazil SD, non-variant-specific): 57.6% (40.7% to 69.7%)		Variant efficacy based sequenced samples for B.1.1.7 and B.1.351 and trial location for P.1. (Brazil)	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext">www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext</a> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext">www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext</a> <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160">papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160</a> <a href="https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-background-2021.1">www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-background-2021.1</a>
Johnson & Johnson	Trial (USA, SA, Brazil): 66.1% (55.0% to 74.8%)	Trial (USA): 72.0% (58.2% to 81.7%)				Trial (USA, SA, Brazil): 65.5% (39.9% to 81.1%)	Trial (USA): 85.9% (9.4% to 99.7%)		Trial (SA): 64.0% (41.2% to 78.7%)	Trial (SA): 81.7% (46.2% to 95.4%)	Trial (Brazil): 68.1% (48.8% to 80.7%)	Trial (Brazil): 87.6% (7.8% to 99.7%)		Efficacy is based on 28+ day outcomes Variant efficacy based on trial location (USA, Brazil, South Africa): 94.5% of sequenced samples in South Africa were B.1.351 69.4% of sequenced samples in Brazil were P.1 96.4% of sequenced samples in USA were D614G	<a href="https://www.fda.gov/media/146218/download">www.fda.gov/media/146218/download</a> <a href="https://www.fda.gov/media/146217/download">www.fda.gov/media/146217/download</a> <a href="https://www.fda.gov/media/146219/download">www.fda.gov/media/146219/download</a>
Novavax		Trial (UK): 89.3% (75.2% to 95.4%)						Trial (variant-specific): 86% (59.2% to 95.0%)	Trial (SA): 49.4% (6.1% to 72.8%)					93% of sequenced samples in South Africa were B.1.351	<a href="https://ir.novavax.com/static-files/2f6f14cb-3205-4719-b28c-1711793b9782">ir.novavax.com/static-files/2f6f14cb-3205-4719-b28c-1711793b9782</a>
Sputnik V			Trial: 91.6% (85.6% to 95.2%)				Trial: 100% (94.4% to 100%)				Trial: 100% (94.4% to 100%)			Trial assumed to apply to wildtype/D614G/B.1.1.7 outcomes	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext">www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext</a>
CoronaVac		Trial (Indonesia): 65.3% (25 cases) Trial (Turkey): 91.3% (29 cases)										Trial (Brazil): 50.3% (252 cases; 167 placebo, 85 vaccine)		Unpublished reports	<a href="https://www.nature.com/articles/d41586-021-00094-z">www.nature.com/articles/d41586-021-00094-z</a>
Sinopharm	Trial: 72.5% (not reported)													Unpublished reports	<a href="https://www.scmp.com/news/china/science/article/3122980/covid-19-vaccines-made-chinas-sinopharm-cansino-release-efficacy">www.scmp.com/news/china/science/article/3122980/covid-19-vaccines-made-chinas-sinopharm-cansino-release-efficacy</a>
CanSinoBio	Trial: 65.7% (not reported)													Unpublished reports	<a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-65-7-effective-in-global-trials-pakistan-official-says-idUSKBN2481ND">www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-65-7-effective-in-global-trials-pakistan-official-says-idUSKBN2481ND</a>